Lirilumab, a novel anti-cancer antibody targeting LAG-3, represents a promising breakthrough in immunology. Its development began with preliminary investigations showing LAG-3's role in immune suppression. Preclinical https://lirilumab-reagent639084.wikicommunications.com/user